Showing results (551-560 of 5,255) with videos related to

Sort By:
Pageof 526
Oncology|July 8, 2011
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patientsSoo Hyeon Lee, Myung Hee Chang, Kyung Kee Baek, et al.
Oncology|November 2, 2011
Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapyNerbil Kilic, Mary Elizabeth Myrick, Seraina Margaretha Schmid, et al.
Oncology|November 2, 2011
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centersJens Huober, Michael Baumann, Christoph Rochlitz, et al.
Oncology|October 12, 2011
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trialsMontserrat Blanco Codesido, Andre Tesainer Brunetto, Sophia Frentzas, et al.
Oncology|October 12, 2011
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapyYu-Yun Shao, Zhong-Zhe Lin, Te-Jung Chen, et al.
Oncology|October 12, 2011
Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literatureDavid M Hyman, Gerald A Soff, Lewis J Kampel
Oncology|August 11, 2011
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancerD Lorusso, S Mainenti, A Pietragalla, et al.
Oncology|August 11, 2011
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profilesHyo Song Kim, Min Hee Hong, Kiyeol Kim, et al.
Oncology|August 9, 2011
I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP scoreAhmed O Kaseb, James L Abbruzzese, Jean-Nicolas Vauthey, et al.
Oncology|November 8, 2011
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgeryKohei Shitara, Keitaro Matsuo, Chihiro Kondo, et al.
Pageof 526